

# Clovis Lusivika-Nzinga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315657/publications.pdf>

Version: 2024-02-01

6  
papers

35  
citations

2257263

3  
h-index

2053342

5  
g-index

6  
all docs

6  
docs citations

6  
times ranked

100  
citing authors

#	ARTICLE	IF	CITATIONS
1	The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1489-1492.	1.0	13
2	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 1017-13.	0.7	10
3	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	1.3	6
4	Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	1.0	5
5	Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1050-1050.	1.9	1
6	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir new clues from Europe. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 659-659.	1.9	0